University of Southern California

Other

Ethicon, Gmbh

Gaffney, Kevin J.

Rodgers, Kathleen, E.

Louie, Stan G.

Petasis, Nicos A.

Dizerega, Gere, S.

Gere S DiZerega

Kathleen Elizabeth Rodgers

Stan G Louie

Nicos A Petasis

Kevin J Gaffney

Mark Salman Humayun

Shalaby Wahba Shalaby

Warren D Sheffield

Douglas B Johns

LeRoy L Richer

Walid Fouad Ahmed Abdallah

Brett Lund

Eve Kelland

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer. In particular, the invention provides compounds, methods and compositions for the treatment of metabolic diseases and disorders, such as diabetes mellitus, diabetes-related cardiovascular disorders, diabetes-related dermal ulcerations, diabetes related hypertension, and diabetes-related ophthalmic diseases.

Methods, compounds, and compositions for the treatment of angiotensin-related diseases

This invention provides methods, compounds and compositions for the treatment of musculoskeletal disease, muscle dysfunction, muscle-wasting disease or disorder, including hereditary myopathy, neuromuscular disease, muscular dystrophy, muscular atrophy, drug-induced myopathy, and related disease, disorder or condition that causes a decrease in muscle strength, comprising the use of heterocyclic non-peptidic compounds that act as Mas agonists and/or mimics of angiotensin 1-7.

Methods, compounds, and compositions for the treatment of musculoskeletal diseases

Disclosed herein are methods for treating eye injuries by administering one or more angiotensin peptides to a subject with an eye injury.

Accelerated healing of eye injuries by angiotensin peptides

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.

The present invention provides methods for limiting development of skin wounds, and also for treatment of one or more of erythemas, blisters, rashes, pruritis, contact dermatitis, psoriasis, eczema, acne, and athlete's foot.

Methods for limiting development of a skin wound

The present invention provides methods for treating or limiting development of multiple sclerosis by administering angiotensin peptides to a subject with multiple sclerosis or at risk of developing multiple sclerosis.

Methods for treating multiple sclerosis

The present invention provides methods for treating a subject that has suffered combined exposure to total body ionizing irradiation and burns by administering a peptide of at least 5 amino acids of a peptide of SEQ ID NO:1 (Asp-Arg-Nle-Tyr-Ile-His-Pro), or a pharmaceutical salt thereof in an amount effective to treat the radiation effects and/or the burn.

Methods for treating combined radiation and thermal injury

The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.

Methods for treating diabetic foot ulcers

The present invention provides improved methods, kits, and pharmaceutical compositions for increasing hematopoietic cell survival and/or reducing or preventing the side effects of chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood following chemotherapy, comprising administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII ATtype 2 receptor agonists to a patient in need of chemotherapy.

Method for treating a patient undergoing chemotherapy

The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII ATtype 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic anemia associated with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases.

Method of promoting erythropoiesis

The present invention provides methods and kits for mitigating radiation induced tissue damage, improving the effectiveness of radiation therapy, to support bone marrow transplantation, and promoting megakaryocyte production and mobilization and platelet production, each method comprising the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII ATtype 2 receptor agonists.

Radiation therapy methods

The present invention provides methods, compounds, and pharmaceutical compositions for inhibiting tumor cell proliferation, by administering an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII ATtype 2 receptor agonists to a subject.

Methods for inhibiting tumor cell proliferation

The present invention provides improved methods, kits, and compositions for enhancing bone, cartilage and cartilage repair, bone and prosthesis implantation, and attachment and fixation of cartilage and cartilage to bone or other tissues, and chondrocyte proliferation composing the administration of an effective amount of angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII), AII analogues, AII fragments or analogues thereof or AII ATtype 2 receptor agonists.

Growing community of inventors

San Luis Obispo, CA, United States of America

Gere S DiZerega